Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This prospective observational cohort study aims to investigate the relationship between immunosenescence and infectious diseases in older adults. Individuals aged 60 years and older, including elderly patients with infections and healthy controls, will be enrolled and followed longitudinally.
Clinical information, laboratory test results, and health assessment data will be collected. Biological specimens, including peripheral blood, urine, stool, sputum, and nasopharyngeal swabs, will be obtained during enrollment and follow-up. Participants will undergo regular assessments of health status, infection events, and aging-related clinical characteristics.
The study will evaluate age-related changes in immune function, immune cell composition, immune receptor repertoires, epigenetic characteristics, metabolic profiles, and respiratory and gut microbiota. By integrating clinical and multi-omics data, the study aims to identify biomarkers associated with immunosenescence, susceptibility to infection, disease severity, and clinical outcomes in older adults.
The results are expected to improve understanding of the mechanisms linking aging, immune dysfunction, and infectious diseases, and to support the development of predictive models and preventive strategies for infection management and healthy aging in elderly populations.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Infected Older Adults | Elderly participants aged 60 years or older who meet the study criteria for infectious diseases at enrollment or during the study follow-up period. | ||
| Healthy Older Controls | Adults aged 60 years or older who are living independently or receiving routine health examinations and have no evidence of active infection at enrollment or during the study follow-up period. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of peripheral immune cell subset | Proportion of peripheral blood immune cell subsets in the infection group versus the healthy control group. | Baseline to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| DNA methylation level | Chromatin accessibility of peripheral blood mononuclear cells. | Baseline to 5 years |
| Metabolite abundance (metabolomic profiling) | Abundance of metabolites in plasma and urine. |
Not provided
Inclusion Criteria for the Healthy Control Group
Inclusion Criteria for the Infection Group 1.Age: 60 years or older; no gender restrictions. 2. Clinically diagnosed with an infectious disease by the treating physician. 3. The participant provides informed consent and signs the relevant documents.
-------------- Exclusion Criteria for the Healthy Control Group
Exclusion Criteria for the Infection Group
Not provided
Not provided
Not provided
Adults aged 60 years and older
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jingwen Ai, MD | Contact | 86+13764990804 | jingwenai1990@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Huashan Hospital | Recruiting | Shanghai | Shanghai Municipality | 200040 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline to 5 years |
| Respiratory and gut microbiota diversity measured by microbiome sequencing | Diversity of respiratory tract and gut microbiota, measured by microbiome sequencing and reported as the Shannon diversity index. | Baseline to 5 years |